biostudies-literatureUnknown38(6)Bouguen G<h4>Background and objectives</h4>Biosimilars are cost-effective alternatives to reference products for patients with inflammatory bowel diseases (IBD) and chronic inflammatory rheumatic diseases (CIRD), but patient beliefs can affect adherence to the transition. This study aimed to explore patient experience and satisfaction after switching to CT-P17, a high-concentration (100 mg/mL), citrate-free adalimumab biosimilar.<h4>Patients and methods</h4>This observational, multicenter, prospective French study included adult patients with IBD or CIRD who switched to CT-P17 from reference adalimumab (R-ADA; 100 mg/mL) or a low-concentration adalimumab biosimilar (ADA-BioS; 50 mg/mL). Patients completed online questionnaires to assess treatment perceptions, satisfaction, and tolerance at study inBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy867-878https://www.ebi.ac.uk/biostudies/studies/S-EPMC11530508biostudies-literaturePatient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.PMC11530508Nancey SBouguen GAbitbol VVuitton LMarotte HFilippi JBenkhalifa SSenbel EFoulley LRoblin XMathieu NDenis AGossec LBonnaud GDellal ABouhnik YNahon SHabauzit CfalsePatient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.<h4>Background and objectives</h4>Biosimilars are cost-effective alternatives to reference products for patients with inflammatory bowel diseases (IBD) and chronic inflammatory rheumatic diseases (CIRD), but patient beliefs can affect adherence to the transition. This study aimed to explore patient experience and satisfaction after switching to CT-P17, a high-concentration (100 mg/mL), citrate-free adalimumab biosimilar.<h4>Patients and methods</h4>This observational, multicenter, prospective French study included adult patients with IBD or CIRD who switched to CT-P17 from reference adalimumab (R-ADA; 100 mg/mL) or a low-concentration adalimumab biosimilar (ADA-BioS; 50 mg/mL). Patients completed online questionnaires to assess treatment perceptions, satisfaction, and tolerance at study in2024-01-01T00:00:00Z2024 Nov2026-06-01T06:56:05.153Z2025-04-21T21:45:48.291ZS-EPMC115305083932280210.1007/s40259-024-00681-2